Elanco & Zoetis

Elanco: Elanco is a competitor to Zoetis, with its products Credelio Quattro and Ilunocitinib gaining market share from Zoetis' key companion animal products.

Zoetis: Zoetis is facing a class action lawsuit for alleged securities fraud and unlawful business practices, which has negatively impacted its stock price and reputation. The company also cut its full-year 2026 profit guidance due to a challenging operating environment.

Elanco: Elanco>>> shares rose as the company produces one of the animal treatments authorized for emergency use, suggesting potential benefits if the outbreak becomes more severe and increases demand for livestock drugs.

Zoetis: Zoetis>>> shares also rose, benefiting from the potential increased spending on livestock drugs if the screwworm outbreak necessitates widespread treatment.

Elanco: Elanco rose 1.5% on expectations for stronger profits following the confirmation of the New World screwworm fly in south Texas.

Zoetis: Rose 5.1% on screwworm outbreak.